All Pharmaceutical Microbiology articles – Page 18
-
NewsCollaborative infectious disease research takes aim at bystander cells
Researchers examining disease infection in bystander cells were granted nearly $500,000 from the Chan Zuckerberg Initiative to advance their work.
-
NewsNovo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
The Novo Nordisk Foundation is committing up to $25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this ...
-
NewsNew approach could address antibiotic resistance to Mycobacterium abscessus
Scientists have designed new versions of the drug spectinomycin that overcome efflux, the main mechanism driving resistance.
-
NewsCalibr announces license agreement with Gilead to develop long-acting HIV antiviral agent
Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care
-
News Study demonstrates potency of synthetic antibiotic against serious chronic infections
A new synthetic antibiotic is shown to be more effective than established drugs against ‘superbugs’ such as MRSA, a new study shows.
-
News“Honey, I shrunk the cookbook” – new approach to vaccine development
Bioinformaticians have presented a method for identifying epitopes that promise safe immunisation across the broadest possible population group.
-
NewsResearchers use AI to identify a new class of antibiotic candidates
Using deep learning, researchers have discovered a class of compounds that can kill methicillin-resistant Staphylococcus aureus (MRSA) grown in a lab dish and in two mouse models of MRSA infection.
-
NewsAntibiotic substance isolated from bacteria in the human nose
Researchers have discovered a novel antibiotic substance from the human nose that can be used against pathogenic bacteria. Epifadin is produced from specific strains of the bacterial species Staphylococcus epidermidis.
-
NewsNanoparticles with antibacterial action shorten duration of tuberculosis treatment
A low-cost technology involving nanoparticles loaded with antibiotics and other antimicrobial compounds that can be used in multiple attacks on infections by the bacterium responsible for most cases of tuberculosis has been developed.
-
NewsResearchers reveal breakthrough in the development of drug for sleeping sickness
A novel way to attack the trypanosome parasite through its ribosome prevents the parasite from producing essential proteins, thus impairing its ability to survive.
-
NewsNew weapon against the super tough C diff bacteria shows promise
A researcher has demonstrated that a newer generation tetracycline antibiotic, Omadacycline, may be a promising tool in combating the resilient bacteria Clostridioides difficile (C diff), which causes an infection often picked up in hospitals.
-
NewsMedicinal plants offer hope for drug discovery and development against COVID-19
A new book offers insights into treating SARS-CoV-2 infections and respiratory problems, highlighting prospective drug discovery opportunities based on bioactive components from medicinal plants and herbal remedies.
-
NewsNew oral treatment reduces duration and symptoms of mild COVID-19
The treatment acts on the replication mechanism of SARS-CoV-2, the virus responsible for the disease, and reduces the severity and duration of some of the symptoms. In addition, it can be useful to treat the different mutations detected.
-
NewsDenovAI uses artificial intelligence to discover therapeutic antibodies
Kashif Sadiq has founded a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
-
NewsTeam-up of two new substances paves the way for new antibiotics
A new study shows how a combination of two new substances effectively kills methicillin-resistant Staphylococcus aureus (MRSA).
-
NewsNovel compounds promise success in the fight against tuberculosis and depression
Scientists have shown that a specific polyprenylated polycyclic acylphloroglucinol, PPAP53, is able to activate human macrophages to fight resistant tuberculosis bacteria without being toxic to the macrophages themselves.
-
OpinionCatch-22: the FDA, probiotics, and preterm infants
As the FDA issues warning letters about probiotic products sold for use in hospitalized preterm infants, families of babies threatened by necrotizing enterocolitis (NEC) now face a deadly Catch-22 situation.
-
NewsFungus-fighting protein could help overcome severe autoimmune disease and cancer
A protein in the immune system programmed to protect the body from fungal infections is also responsible for exacerbating the severity of certain autoimmune diseases such as irritable bowel disease (IBS) and type 1 diabetes.
-
NewsHIV drug could prevent coronaviruses, study finds
New research has shown how an HIV drug could stop many coronavirus diseases, including the SARS-CoV-2 variants, when given to infected cells at the right concentration.
-
NewsIce core proposal could revolutionise antibiotic discovery
A perspective article outlines a revolutionary approach to antibiotic discovery using ice cores, at a time when antimicrobial resistance (AMR) is projected to cause 10 million deaths per year by 2050.